Financial Snapshot

Revenue
$2.753B
TTM
Gross Margin
79.04%
TTM
Net Earnings
$322.3M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
427.1%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$5.413B
Q3 2024
Cash
Q3 2024
P/E
39.33
Nov 29, 2024 EST
Free Cash Flow
$300.8M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Revenue $2.419B $2.096B $1.846B $1.860B $1.704B $1.491B $1.314B $1.110B $889.9M $738.4M $548.5M $500.7M $441.4M $376.3M $324.7M $296.5M $121.6M $84.20M $25.70M $18.60M $12.10M $0.00 $0.00 $9.700M $5.300M $900.0K $0.00
YoY Change 15.42% 13.53% -0.76% 9.18% 14.27% 13.52% 18.31% 24.78% 20.51% 34.63% 9.54% 13.45% 17.3% 15.88% 9.51% 143.83% 44.42% 227.63% 38.17% 53.72% -100.0% 83.02% 488.89%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Revenue $2.419B $2.096B $1.846B $1.860B $1.704B $1.491B $1.314B $1.110B $889.9M $738.4M $548.5M $500.7M $441.4M $376.3M $324.7M $296.5M $121.6M $84.20M $25.70M $18.60M $12.10M $0.00 $0.00 $9.700M $5.300M $900.0K $0.00
Cost Of Revenue $514.9M $483.7M $470.5M $524.3M $359.5M $315.3M $241.8M $209.6M $152.0M $122.3M $95.74M $91.83M $84.02M $70.29M $65.90M $52.50M $18.40M $8.700M $2.600M $4.000M $0.00 $0.00 $0.00
Gross Profit $1.904B $1.612B $1.376B $1.336B $1.345B $1.176B $1.072B $907.2M $737.9M $616.1M $452.7M $408.9M $357.3M $306.0M $258.7M $244.0M $103.2M $75.50M $23.00M $14.70M $12.10M $0.00 $0.00
Gross Profit Margin 78.72% 76.92% 74.52% 71.82% 78.91% 78.86% 81.59% 81.7% 82.92% 83.44% 82.54% 81.66% 80.96% 81.32% 79.67% 82.29% 84.87% 89.67% 89.49% 79.03% 100.0%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Selling, General & Admin $937.3M $854.0M $759.4M $737.7M $680.9M $604.4M $554.3M $473.0M $402.3M $302.2M $235.4M $198.2M $175.4M $151.7M $124.3M $106.6M $77.50M $48.50M $41.60M $37.60M $15.30M $16.90M $6.400M $6.500M $4.800M $3.100M $900.0K
YoY Change 9.75% 12.46% 2.94% 8.33% 12.67% 9.02% 17.2% 17.58% 33.13% 28.38% 18.76% 12.97% 15.62% 22.06% 16.6% 37.55% 59.79% 16.59% 10.64% 145.75% -9.47% 164.06% -1.54% 35.42% 54.84% 244.44%
% of Gross Profit 49.22% 52.97% 55.2% 55.21% 50.64% 51.39% 51.72% 52.14% 54.52% 49.04% 51.98% 48.47% 49.09% 49.59% 48.05% 43.69% 75.1% 64.24% 180.87% 255.78% 126.45%
Research & Development $746.8M $649.6M $628.8M $628.1M $715.0M $696.3M $610.8M $661.9M $634.8M $461.5M $354.8M $302.2M $214.4M $147.3M $115.1M $93.30M $78.60M $66.70M $56.40M $49.80M $53.90M $27.30M $22.60M $38.90M $26.30M $10.30M $1.900M
YoY Change 14.96% 3.31% 0.11% -12.15% 2.68% 14.01% -7.73% 4.27% 37.54% 30.09% 17.39% 40.98% 45.53% 27.98% 23.37% 18.7% 17.84% 18.26% 13.25% -7.61% 97.44% 20.8% -41.9% 47.91% 155.34% 442.11%
% of Gross Profit 39.21% 40.29% 45.71% 47.01% 53.18% 59.21% 56.98% 72.96% 86.03% 74.91% 78.36% 73.91% 59.99% 48.14% 44.49% 38.24% 76.16% 88.34% 245.22% 338.78% 445.45%
Depreciation & Amortization $104.4M $102.0M $108.0M $105.2M $105.3M $95.67M $87.86M $96.91M $47.19M $45.87M $36.01M $34.90M $31.90M $23.30M $20.98M $17.62M $13.65M $11.95M $9.750M $13.28M $9.750M $8.500M $7.000M $5.730M $4.070M $580.0K $10.00K
YoY Change 2.37% -5.62% 2.73% -0.12% 10.06% 8.89% -9.34% 105.38% 2.87% 27.37% 3.19% 9.4% 36.91% 11.06% 19.07% 29.08% 14.23% 22.56% -26.58% 36.21% 14.71% 21.43% 22.16% 40.79% 601.72% 5700.0%
% of Gross Profit 5.48% 6.32% 7.85% 7.87% 7.83% 8.14% 8.2% 10.68% 6.39% 7.44% 7.95% 8.54% 8.93% 7.61% 8.11% 7.22% 13.23% 15.83% 42.39% 90.34% 80.58%
Operating Expenses $1.684B $1.504B $1.388B $1.366B $1.396B $1.301B $1.165B $1.165B $1.037B $763.7M $590.1M $500.4M $389.8M $299.0M $239.5M $199.8M $156.1M $115.2M $98.00M $87.30M $69.20M $44.10M $29.00M $45.40M $31.10M $13.40M $2.800M
YoY Change 12.0% 8.32% 1.64% -2.16% 7.32% 11.64% 0.0% 12.34% 35.8% 29.41% 17.93% 28.37% 30.35% 24.86% 19.87% 27.99% 35.5% 17.55% 12.26% 26.16% 56.92% 52.07% -36.12% 45.98% 132.09% 378.57%
Operating Profit $158.1M $149.6M -$82.34M -$36.77M -$100.5M -$123.5M -$14.70M -$257.9M -$110.7M -$92.89M -$156.0M -$110.2M -$33.89M $544.0K $19.20M $44.20M -$52.90M -$39.70M -$75.00M -$72.60M -$57.10M -$44.10M -$2.800M
YoY Change 5.71% -281.64% 123.97% -63.4% -18.67% 740.3% -94.3% 132.97% 19.17% -40.46% 41.55% 225.21% -6329.78% -97.17% -56.56% -183.55% 33.25% -47.07% 3.31% 27.15% 29.48%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Interest Expense $17.34M $15.97M $15.34M $29.31M $23.46M $43.66M $42.71M $39.50M $38.24M $36.64M $10.45M $7.639M $8.409M $10.82M -$14.80M -$6.400M $37.80M $14.60M -$11.20M -$12.10M -$600.0K $1.500M $1.900M $3.000M -$600.0K $600.0K $100.0K
YoY Change 8.55% 4.13% -47.67% 24.93% -46.27% 2.24% 8.12% 3.28% 4.37% 250.74% 36.76% -9.16% -22.27% -173.09% 131.25% -116.93% 158.9% -230.36% -7.44% 1916.67% -140.0% -21.05% -36.67% -600.0% -200.0% 500.0%
% of Operating Profit 10.96% 10.68% 1988.6% -77.08% -14.48%
Other Income/Expense, Net -$10.54M -$2.050M $11.85M $7.100M $6.900M $2.200M $8.000M $4.900M -$9.300M $300.0K $1.000M -$1.800M $100.0K $500.0K $300.0K -$300.0K
YoY Change 414.05% -117.31% 66.85% 2.9% 213.64% -72.5% 63.27% -152.69% -3200.0% -70.0% -155.56% -1900.0% -80.0% 66.67% -200.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Pretax Income $188.6M $149.6M -$75.35M -$42.32M -$94.81M -$142.7M -$35.88M -$831.1M -$154.7M -$124.9M -$176.5M $45.42M $63.64M $28.66M $600.0K $33.40M -$15.10M -$28.50M -$74.30M -$187.4M -$76.40M -$77.40M -$57.40M -$35.60M -$26.40M -$11.90M -$2.800M
YoY Change 26.07% -298.51% 78.04% -55.36% -33.56% 297.78% -95.68% 437.12% 23.91% -29.25% -488.58% -28.63% 122.06% 4676.5% -98.2% -321.19% -47.02% -61.64% -60.35% 145.29% -1.29% 34.84% 61.24% 34.85% 121.85% 325.0%
Income Tax $20.92M $8.015M -$11.27M -$901.4M -$70.96M -$65.49M $81.17M -$200.8M $17.08M $9.101M -$150.0K -$3.931M $10.21M -$227.3M $1.100M $2.600M $700.0K $100.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income 11.09% 5.36% -8.65% 16.04% -793.15% 183.33% 7.78%
Net Earnings $167.6M $141.6M -$64.08M $859.1M -$23.85M -$77.21M -$117.0M -$630.2M -$171.8M -$134.0M -$176.4M -$114.3M -$53.84M $205.8M -$500.0K $30.80M -$15.80M -$28.50M -$74.30M -$187.4M -$75.80M -$77.50M -$67.60M -$37.40M -$28.10M -$12.30M -$2.800M
YoY Change 18.43% -320.91% -107.46% -3702.4% -69.11% -34.03% -81.43% 266.83% 28.24% -24.03% 54.23% 112.4% -126.16% -41263.8% -101.62% -294.94% -44.56% -61.64% -60.35% 147.23% -2.19% 14.64% 80.75% 33.1% 128.46% 339.29%
Net Earnings / Revenue 6.93% 6.75% -3.47% 46.18% -1.4% -5.18% -8.91% -56.76% -19.31% -18.14% -32.15% -22.84% -12.2% 54.7% -0.15% 10.39% -12.99% -33.85% -289.11% -1007.53% -626.45% -385.57% -530.19% -1366.67%
Basic Earnings Per Share $0.89 $0.76 -$0.35 $4.75 -$0.13 -$0.44 -$0.67 -$3.80 -$1.07 -$0.92 -$0.95 -$0.48 $2.00
Diluted Earnings Per Share $0.87 $0.75 -$0.35 $4.53 -$0.13 -$0.44 -$0.67 -$3.81 -$1.07 -$0.92 -$1.280M -$0.95 -$0.48 $1.73 -$4.985K $297.3K -$164.8K -$336.9K -$1.080M -$2.910M -$1.221M -$1.454M -$1.645M -$1.042M -$939.8K -$546.7K -$345.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997
Cash & Short-Term Investments $1.074B $1.292B $1.014B $1.065B $753.8M $1.084B $1.396B $789.7M $592.6M $945.2M $784.7M $447.8M $195.1M $274.1M $300.7M $560.0M $587.7M $290.4M $48.90M $51.00M $210.4M $78.90M $135.3M $40.20M $63.00M $11.40M $6.900M
YoY Change -16.86% 27.39% -4.84% 41.34% -30.48% -22.33% 76.78% 33.26% -37.3% 20.45% 75.23% 129.52% -28.82% -8.85% -46.3% -4.71% 102.38% 493.87% -4.12% -75.76% 166.67% -41.69% 236.57% -36.19% 452.63% 65.22%
Cash & Equivalents $755.1M $724.5M $587.3M $649.2M $437.4M $494.0M $598.0M $408.3M $397.0M $875.5M $568.8M $180.5M $46.30M $88.10M $167.2M $222.9M $228.3M $89.20M $38.10M $13.10M $121.4M $33.60M $12.50M $16.50M $23.40M $9.400M $6.000M
Short-Term Investments $318.7M $567.0M $426.6M $416.2M $316.4M $590.3M $797.9M $381.3M $195.6M $69.70M $215.9M $267.3M $148.8M $186.0M $133.5M $337.1M $359.3M $201.3M $10.80M $37.90M $89.00M $45.30M $122.8M $23.70M $39.60M $2.000M $900.0K
Other Short-Term Assets $141.4M $104.5M $110.4M $129.9M $130.7M $98.40M $74.00M $61.70M $46.30M $98.80M $72.30M $57.90M $39.80M $26.60M $7.800M $15.40M $2.800M $4.000M $3.300M $27.80M $2.900M $2.100M $2.600M $2.500M $300.0K $700.0K $500.0K
YoY Change 35.28% -5.36% -14.98% -0.61% 32.83% 32.97% 19.94% 33.26% -53.14% 36.65% 24.87% 45.48% 49.62% 241.03% -49.35% 450.0% -30.0% 21.21% -88.13% 858.62% 38.1% -19.23% 4.0% 733.33% -57.14% 40.0%
Inventory $1.107B $894.1M $776.7M $698.5M $680.3M $530.9M $475.8M $355.1M $271.7M $199.5M $162.6M $128.7M $130.1M $109.7M $78.70M $73.20M $32.40M $25.10M $10.90M $2.300M $0.00 $700.0K $100.0K $0.00
Prepaid Expenses
Receivables $633.7M $461.3M $373.4M $448.4M $377.4M $342.6M $261.4M $215.3M $165.0M $144.5M $117.8M $109.1M $104.8M $86.60M $73.50M $84.30M $17.00M $14.70M $5.900M $4.000M $0.00 $1.800M $2.500M $700.0K $100.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $14.10M $9.700M $0.00 $0.00 $0.00 $7.300M $7.100M $4.800M $4.500M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $2.956B $2.751B $2.274B $2.342B $1.942B $2.056B $2.207B $1.422B $1.090B $1.398B $1.137B $743.4M $469.8M $504.3M $467.7M $737.7M $644.3M $334.2M $68.90M $85.20M $213.3M $81.10M $137.9M $44.50M $66.40M $12.80M $7.500M
YoY Change 7.44% 20.98% -2.9% 20.6% -5.55% -6.84% 55.23% 30.49% -22.04% 22.88% 53.0% 58.24% -6.84% 7.83% -36.6% 14.5% 92.79% 385.05% -19.13% -60.06% 163.01% -41.19% 209.89% -32.98% 418.75% 70.67%
Property, Plant & Equipment $1.066B $1.114B $1.082B $1.090B $1.070B $948.7M $896.7M $798.8M $704.2M $523.5M $319.3M $284.5M $269.0M $221.9M $199.1M $125.0M $76.80M $55.50M $37.30M $42.50M $25.20M $28.20M $32.60M $20.70M $25.10M $6.200M $100.0K
YoY Change -4.32% 3.0% -0.71% 1.8% 12.82% 5.8% 12.26% 13.43% 34.52% 63.95% 12.23% 5.76% 21.23% 11.45% 59.28% 62.76% 38.38% 48.79% -12.24% 68.65% -10.64% -13.5% 57.49% -17.53% 304.84% 6100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $611.1M $333.8M $507.8M $285.5M $412.0M $235.9M $385.8M $572.7M $425.7M $97.90M $268.5M $117.1M $94.90M $129.3M $170.3M $2.500M $44.90M $31.50M $32.00M $23.10M $12.00M $1.500M $400.0K $700.0K $0.00
YoY Change 83.06% -34.26% 77.86% -30.7% 74.65% -38.85% -32.63% 34.53% 334.83% -63.54% 129.29% 23.39% -26.6% -24.08% 6712.0% -94.43% 42.54% -1.56% 38.53% 92.5% 275.0% -42.86%
Other Assets $1.717B $1.641B $1.554B $1.517B $612.0M $497.5M $428.9M $479.6M $628.8M $245.5M $301.4M $208.8M $240.2M $250.2M $15.30M $12.60M $18.40M $9.400M $20.50M $20.70M $5.900M $1.300M $1.300M $10.20M $200.0K $100.0K $0.00
YoY Change 4.67% 5.55% 2.45% 147.92% 23.02% 15.99% -10.57% -23.73% 156.13% -18.55% 44.35% -13.07% -4.0% 1535.29% 21.43% -31.52% 95.74% -54.15% -0.97% 250.85% 353.85% 0.0% -87.25% 5000.0% 100.0%
Total Long-Term Assets $3.886B $3.624B $3.729B $3.506B $2.748B $2.371B $2.426B $2.602B $2.640B $1.078B $1.107B $824.9M $835.9M $758.3M $449.5M $169.0M $171.0M $129.2M $126.4M $147.8M $43.00M $29.50M $33.90M $32.40M $37.10M $18.70M $200.0K
YoY Change 7.23% -2.82% 6.36% 27.58% 15.9% -2.27% -6.76% -1.44% 144.92% -2.61% 34.16% -1.32% 10.23% 68.7% 165.98% -1.17% 32.35% 2.22% -14.48% 243.72% 45.76% -12.98% 4.63% -12.67% 98.4% 9250.0%
Total Assets $6.842B $6.375B $6.003B $5.848B $4.690B $4.427B $4.633B $4.024B $3.729B $2.475B $2.244B $1.568B $1.306B $1.263B $917.2M $906.7M $815.3M $463.4M $195.3M $233.0M $256.3M $110.6M $171.8M $76.90M $103.5M $31.50M $7.700M
YoY Change
Accounts Payable $683.1M $231.2M $193.0M $191.4M $241.0M $208.1M $161.7M $198.5M $186.2M $144.4M $36.90M $24.00M $5.000M $7.600M $900.0K $1.200M $2.300M $500.0K $900.0K $400.0K $100.0K $4.300M $4.600M $3.100M $0.00 $100.0K
YoY Change 195.43% 19.81% 0.84% -20.58% 15.81% 28.7% -18.54% 6.61% 28.95% 291.33% 53.75% -34.21% 744.44% -25.0% -47.83% 360.0% -44.44% 125.0% 300.0% -97.67% -6.52% 48.39% -100.0%
Accrued Expenses $322.8M $317.8M $277.1M $266.3M $287.9M $213.0M $201.6M $158.9M $197.9M $81.90M $136.8M $117.1M $75.60M $67.90M $61.50M $57.30M $47.10M $26.30M $18.30M $24.40M $9.700M $3.800M $2.200M $2.000M $2.000M $600.0K $0.00
YoY Change 1.57% 14.72% 4.04% -7.5% 35.16% 5.65% 26.87% -19.71% 141.64% -40.13% 16.82% 54.89% 11.34% 10.41% 7.33% 21.66% 79.09% 43.72% -25.0% 151.55% 155.26% 72.73% 10.0% 0.0% 233.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $23.40M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $493.9M $2.287M $2.266M $2.900M $365.1M $0.00 $360.9M $22.50M $0.00 $70.70M $6.300M $6.800M $11.30M $42.80M $2.700M $2.900M $1.600M $0.00 $0.00 $0.00 $0.00
YoY Change 21494.97% 0.93% -21.86% -99.21% -100.0% 1504.0% -100.0% 1022.22% -7.35% -39.82% -73.6% 1485.19% -6.9% 81.25%
Total Short-Term Liabilities $1.177B $588.9M $539.8M $492.5M $932.5M $523.2M $816.5M $439.3M $445.5M $235.7M $183.3M $170.4M $94.10M $83.80M $78.20M $130.1M $61.50M $46.00M $40.40M $70.10M $12.80M $6.800M $8.300M $6.900M $5.100M $2.000M $300.0K
YoY Change 99.87% 9.09% 9.61% -47.18% 78.23% -35.92% 85.86% -1.39% 89.01% 28.59% 7.57% 81.08% 12.29% 7.16% -39.89% 111.54% 33.7% 13.86% -42.37% 447.66% 88.24% -18.07% 20.29% 35.29% 155.0% 566.67%
Long-Term Debt $593.1M $1.083B $1.081B $1.079B $492.9M $830.4M $813.5M $660.8M $662.3M $642.9M $655.6M $324.9M $348.3M $377.5M $497.2M $497.4M $563.9M $292.5M $212.9M $228.0M $125.7M $5.200M $4.000M $100.0K $100.0K $100.0K $0.00
YoY Change -45.25% 0.2% 0.17% 118.95% -40.64% 2.08% 23.11% -0.23% 3.02% -1.94% 101.79% -6.72% -7.74% -24.07% -0.04% -11.79% 92.79% 37.39% -6.62% 81.38% 2317.31% 30.0% 3900.0% 0.0% 0.0%
Other Long-Term Liabilities $119.9M $99.83M $111.7M $170.3M $142.2M $105.5M $194.4M $157.3M $77.30M $68.80M $64.20M $57.30M $53.10M $47.50M $17.20M $2.600M $2.100M $7.100M $19.50M $2.900M $0.00
YoY Change 20.14% -10.65% -34.39% 19.76% 34.79% -45.73% 23.59% 103.49% 12.35% 7.17% 12.04% 7.91% 11.79% 176.16% 561.54% 23.81% -70.42% -63.59% 572.41%
Total Long-Term Liabilities $713.0M $1.183B $1.193B $1.250B $635.1M $935.9M $1.008B $818.1M $739.6M $711.7M $719.8M $382.2M $401.4M $425.0M $514.4M $500.0M $566.0M $299.6M $232.4M $230.9M $125.7M $5.200M $4.000M $100.0K $100.0K $100.0K $0.00
YoY Change -39.73% -0.82% -4.54% 96.74% -32.14% -7.14% 23.2% 10.61% 3.92% -1.13% 88.33% -4.78% -5.55% -17.38% 2.88% -11.66% 88.92% 28.92% 0.65% 83.69% 2317.31% 30.0% 3900.0% 0.0% 0.0%
Total Liabilities $1.890B $1.772B $1.733B $1.742B $1.568B $1.459B $1.825B $1.257B $1.329B $947.5M $903.0M $552.6M $532.7M $545.4M $595.0M $630.0M $627.6M $345.6M $272.8M $300.9M $138.5M $12.10M $12.30M $6.900M $5.200M $2.100M $300.0K
YoY Change 6.67% 2.27% -0.54% 11.12% 7.44% -20.02% 45.1% -5.35% 40.21% 4.93% 63.41% 3.74% -2.33% -8.34% -5.56% 0.38% 81.6% 26.69% -9.34% 117.26% 1044.63% -1.63% 78.26% 32.69% 147.62% 600.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $12.676 Billion

About BIOMARIN PHARMACEUTICAL INC

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,401 full-time employees. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Industry: Pharmaceutical Preparations Peers: ALNYLAM PHARMACEUTICALS, INC. Sarepta Therapeutics, Inc. BIOGEN INC. Biohaven Pharmaceutical Holding Co Ltd. INCYTE CORP Moderna, Inc. NEUROCRINE BIOSCIENCES INC Seagen Inc. VERTEX PHARMACEUTICALS INC / MA